BELITE BIO, INC (BLTE)
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Belite Bio, Inc
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
Tinlarebant, Placebo
Stargardt Disease 1
NCT05244304Enrollment104StartMar 2022Primary CompletionAug 2025CompletionSep 2025 - Phase 3Active, not recruiting
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Tinlarebant, Placebo
Geographic Atrophy
NCT05949593Enrollment429StartJul 2023Primary CompletionJun 2027est.CompletionAug 2027est. - Phase 2/3Active, not recruiting
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
Tinlarebant, Placebo
STGD1, Stargardt Disease 1
NCT06388083Enrollment60StartJul 2024Primary CompletionFeb 2028est.CompletionFeb 2028est. - Phase 1Completed
Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults
BPN-14967, Placebo
Healthy Volunteers
NCT04005807Enrollment40StartJul 2019Primary CompletionDec 2019CompletionDec 2019
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | Tinlarebant, Placebo | NCT05244304 |
| Phase 3 | Active, not recruiting | Tinlarebant, Placebo | NCT05949593 |
| Phase 2/3 | Active, not recruiting | Tinlarebant, Placebo | NCT06388083 |
| Phase 1 | Completed | BPN-14967, Placebo | NCT04005807 |